Drug Profile
Research programme: monoclonal antibody therapeutics - CellAct Pharma/Medarex
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GenPat77 Pharmacogenetics; Medarex
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Germany (Parenteral)
- 12 Oct 2009 Preclinical development is ongoing in Germany
- 29 Aug 2006 Preclinical trials in Autoimmune disorders in Germany (unspecified route)